RE: BCG Article first published online: 3 JAN 2013 CT. Great find. Too bad it did not mention Urocidin in the BCG-CW section.
With the response rate of Urocidin, It seems MCC complex was able to overcome the hydrophobic (afraid-0f-water) properties and the negative charge of a lot of these engineered extracts and make it more soluable and readily adhere to and internalized into the urethial and cancer cells. The only lacking Urocidin is the lack of infection property. This mechansm is mentioned as one of the three that are responsible to BCG's anti-tumor activity. The lack of infection means it lacks the ability to continually produce more immune-stimulating agents after instillation. Hence, I posted the possibility that Urocidin might not be as effective as BCG if compared head to head.
BTW, when Endo took over the trial. Dr. Morales was kicked out of the loop. My understanding is now with Urocidin back in our control, Morales is back in and helping the development. That to me is a very good thing.
C
anada biopharma is lucky to have Urocidin. It has a great potential to be a drug that can change the tumor therapy. HC knows it and I think it will be in a more co-operative mood with Endo out of the picture. As I said, Canada's prestige and jobs are on the line here. The government should help.